Abstract
Imatinib and other Abl tyrosine kinase inhibitors (TKIs), such as dasatinib and nilotinib, have significantly improved the outcome of patients with chronic myeloid leukemia. Imatinib and dasatinib are currently Food and Drug Administration (FDA) approved, and nilotinib is expected to gain FDA approval soon. In addition, several other Abl TKIs are being evaluated in various clinical trials. Imatinib has also shown efficacy in the therapy of gastrointestinal stromal tumors, Philadelphia chromosome-positive acute lymphocytic leukemia and hypereosinophilic syndrome. Because of their efficacy, more patients will receive Abl TKIs for a longer period of time. Imatinib was FDA approved after a short follow-up because of its exceptional efficacy and safety profile. The most common adverse events reported included fluid retention, fatigue, diarrhea, and muscle cramps. With longer follow-up, issues related to the long-term use of imatinib have been discussed. Our aim is to review the emerging safety issues of Abl TKIs after a longer follow-up.
| Original language | English (US) |
|---|---|
| Pages (from-to) | S105-S112 |
| Journal | Clinical Lymphoma and Myeloma |
| Volume | 7 |
| Issue number | SUPPL. 3 |
| DOIs | |
| State | Published - Mar 2007 |
Fingerprint
Keywords
- Chronic myeloid leukemia
- Gastrointestinal stromal tumors
- Side effects
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. / Atallah, Ehab; Kantarjian, Hagop; Cortes, Jorge.
In: Clinical Lymphoma and Myeloma, Vol. 7, No. SUPPL. 3, 03.2007, p. S105-S112.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors
AU - Atallah, Ehab
AU - Kantarjian, Hagop
AU - Cortes, Jorge
PY - 2007/3
Y1 - 2007/3
N2 - Imatinib and other Abl tyrosine kinase inhibitors (TKIs), such as dasatinib and nilotinib, have significantly improved the outcome of patients with chronic myeloid leukemia. Imatinib and dasatinib are currently Food and Drug Administration (FDA) approved, and nilotinib is expected to gain FDA approval soon. In addition, several other Abl TKIs are being evaluated in various clinical trials. Imatinib has also shown efficacy in the therapy of gastrointestinal stromal tumors, Philadelphia chromosome-positive acute lymphocytic leukemia and hypereosinophilic syndrome. Because of their efficacy, more patients will receive Abl TKIs for a longer period of time. Imatinib was FDA approved after a short follow-up because of its exceptional efficacy and safety profile. The most common adverse events reported included fluid retention, fatigue, diarrhea, and muscle cramps. With longer follow-up, issues related to the long-term use of imatinib have been discussed. Our aim is to review the emerging safety issues of Abl TKIs after a longer follow-up.
AB - Imatinib and other Abl tyrosine kinase inhibitors (TKIs), such as dasatinib and nilotinib, have significantly improved the outcome of patients with chronic myeloid leukemia. Imatinib and dasatinib are currently Food and Drug Administration (FDA) approved, and nilotinib is expected to gain FDA approval soon. In addition, several other Abl TKIs are being evaluated in various clinical trials. Imatinib has also shown efficacy in the therapy of gastrointestinal stromal tumors, Philadelphia chromosome-positive acute lymphocytic leukemia and hypereosinophilic syndrome. Because of their efficacy, more patients will receive Abl TKIs for a longer period of time. Imatinib was FDA approved after a short follow-up because of its exceptional efficacy and safety profile. The most common adverse events reported included fluid retention, fatigue, diarrhea, and muscle cramps. With longer follow-up, issues related to the long-term use of imatinib have been discussed. Our aim is to review the emerging safety issues of Abl TKIs after a longer follow-up.
KW - Chronic myeloid leukemia
KW - Gastrointestinal stromal tumors
KW - Side effects
UR - http://www.scopus.com/inward/record.url?scp=34249653546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249653546&partnerID=8YFLogxK
U2 - 10.3816/CLM.2007.s.010
DO - 10.3816/CLM.2007.s.010
M3 - Article
C2 - 17382019
AN - SCOPUS:34249653546
VL - 7
SP - S105-S112
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
SN - 2152-2650
IS - SUPPL. 3
ER -